Literature DB >> 19789836

Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus.

Kohichiroh Yasui1, Yuichi Harano, Hironori Mitsuyoshi, Kazuhiro Tsuji, Mio Endo, Tomoaki Nakajima, Masahito Minami, Yoshito Itoh, Yoh Zen, Yasuni Nakanuma, Toshikazu Yoshikawa, Takeshi Okanoue.   

Abstract

PURPOSE: Steatosis is a histological finding associated with the progression of chronic hepatitis C. The aims of this study were to elucidate risk factors associated with steatosis and to evaluate the association between steatosis and hepatic expression of genes regulating lipid metabolism.
METHODS: We analyzed 297 Japanese patients infected with hepatitis C virus and a subgroup of 100 patients who lack metabolic factors for steatosis. We determined intrahepatic mRNA levels of 18 genes regulating lipid metabolism in these 100 patients using real-time reverse transcription-polymerase chain reaction. Levels of peroxisome proliferator-activated receptor alpha and sterol regulatory element-binding protein 1 proteins were assessed by immunohistochemistry.
RESULTS: Steatosis was present in 171 (57%) of 297 patients. The presence of steatosis was independently associated with a higher body mass index, higher levels of gamma-glutamyl transpeptidase and triglyceride, and a higher fibrosis stage. Steatosis was present in 43 (43%) of 100 patients lacking metabolic factors. Levels of mRNA and protein of peroxisome proliferator-activated receptor alpha, which regulates beta-oxidation of fatty acid, were lower in patients with steatosis than in patients without steatosis.
CONCLUSIONS: These findings indicate that impaired degradation of lipid may contribute to the development of hepatitis C virus-related steatosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19789836     DOI: 10.1007/s00535-009-0133-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  42 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  Nonalcoholic fatty liver disease.

Authors:  Jeanne M Clark; Frederick L Brancati; Anna Mae Diehl
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

3.  Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity.

Authors:  Takeya Tsutsumi; Tetsuro Suzuki; Takashi Shimoike; Ryosuke Suzuki; Kyoji Moriya; Yoshizumi Shintani; Hajime Fujie; Yoshiharu Matsuura; Kazuhiko Koike; Tatsuo Miyamura
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

4.  Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis.

Authors:  Silvia Mirandola; Stefano Realdon; Jahangir Iqbal; Martina Gerotto; Francesca Dal Pero; Gladis Bortoletto; Moira Marcolongo; Alessandro Vario; Christian Datz; M Mahmood Hussain; Alfredo Alberti
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.

Authors:  Douglas S Lee; Jane C Evans; Sander J Robins; Peter W Wilson; Irene Albano; Caroline S Fox; Thomas J Wang; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-09       Impact factor: 8.311

7.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

Authors:  Hervé Lerat; Masao Honda; Michael R Beard; Kim Loesch; Jiaren Sun; Yan Yang; Michiari Okuda; Rainer Gosert; Shu-Yuan Xiao; Steven A Weinman; Stanley M Lemon
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

8.  Impact of steatosis on progression of fibrosis in patients with mild hepatitis C.

Authors:  Laetitia Fartoux; Olivier Chazouillères; Dominique Wendum; Raoul Poupon; Lawrence Serfaty
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

9.  Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.

Authors:  Thierry Poynard; John McHutchison; Michael Manns; Rob P Myers; Janice Albrecht
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

10.  Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients.

Authors:  Johan Westin; Hans Nordlinder; Martin Lagging; Gunnar Norkrans; Rune Wejstål
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

View more
  18 in total

Review 1.  The interaction between HCV and nuclear receptor-mediated pathways.

Authors:  Zoe Raglow; Carly Thoma-Perry; Richard Gilroy; Yu-Jui Yvonne Wan
Journal:  Pharmacol Ther       Date:  2011-05-18       Impact factor: 12.310

2.  Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy.

Authors:  Rie Osaki; Takashi Nishimura; Takayuki Takeuchi; Hirotsugu Imaeda; Yoshiaki Okumura; Makoto Shioya; Tamio Nakahara; Shigeki Bamba; Shinobu Nakajo; Yoshihide Fujiyama; Akira Andoh
Journal:  Exp Ther Med       Date:  2011-04-07       Impact factor: 2.447

3.  Lipid metabolism and body composition in Gclm(-/-) mice.

Authors:  Eric L Kendig; Ying Chen; Mansi Krishan; Elisabet Johansson; Scott N Schneider; Mary Beth Genter; Daniel W Nebert; Howard G Shertzer
Journal:  Toxicol Appl Pharmacol       Date:  2011-09-24       Impact factor: 4.219

4.  MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection.

Authors:  Ayumi Asada; Makoto Shioya; Rie Osaki; Takashi Nishimura; Takayuki Takeuchi; Yoshiaki Okumura; Akira Andoh
Journal:  Biomed Rep       Date:  2014-12-17

5.  Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma.

Authors:  Jian-Min Wu; Nicholas J Skill; Mary A Maluccio
Journal:  HPB (Oxford)       Date:  2010-11       Impact factor: 3.647

6.  Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C.

Authors:  Kohichiroh Yasui; Takahisa Kawaguchi; Toshihide Shima; Hironori Mitsuyoshi; Kojiro Seki; Rei Sendo; Masayuki Mizuno; Yoshito Itoh; Fumihiko Matsuda; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2014-11-26       Impact factor: 7.527

7.  Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections.

Authors:  Tapas Patra; Reina Sasaki; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

Review 8.  Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.

Authors:  Yuki Haga; Tatsuo Kanda; Reina Sasaki; Masato Nakamura; Shingo Nakamoto; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

Review 9.  Immunologic, metabolic and genetic factors in hepatitis C virus infection.

Authors:  Nora A Fierro; Karina Gonzalez-Aldaco; Rafael Torres-Valadez; Erika Martinez-Lopez; Sonia Roman; Arturo Panduro
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 10.  Intestinal Barrier and Permeability in Health, Obesity and NAFLD.

Authors:  Piero Portincasa; Leonilde Bonfrate; Mohamad Khalil; Maria De Angelis; Francesco Maria Calabrese; Mauro D'Amato; David Q-H Wang; Agostino Di Ciaula
Journal:  Biomedicines       Date:  2021-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.